Bridging the Horizon is a virtual round table programme that brings together innovation leaders from Europe, the UK, and Israel to create a working group and win a grant. As part of the round table series, influential researchers, corporates and government executives from Europe, the UK, and Israel engage in intimate round table discussions surrounding Horizon Europe calls, aiming to increase consortium creation and submissions.
The goal of the EU’s Mission on Cancer is to enhance the well-being of over 3 million individuals by 2030, focusing on prevention, treatment, and improving the lives of cancer patients and their families. Key objectives encompass understanding the disease, preventing avoidable cases, optimizing diagnostic and treatment methods, promoting quality of life, and ensuring fair access across all fronts.
HORIZON-MISS-2024-CANCER-01-03:
Accessible and affordable risk predictor tests to advance early detection of heritable cancers in European regions.
Read more about the call
HORIZON-MISS-2024-CANCER-01-05:
Improving the understanding and management of late-effects in adolescents and young adults (AYA) with cancer.
Read more about the call
Meet potential consortium building partners
Pitch your organisation to experienced and influential participants
Organic and effective matchmaking
Access to partners' broad networks in Israel, the UK, and Europe
Pre-paid consultation with a Horizon Europe expert to craft a winning bid
10:00-10:25
Horizon Europe as a funding source & tips for a winning bid
10:25-10:35
Deep dive into the Horizon Europe selected open calls
10:35-11:30
Introduce yourself: 3-minute pitch for each organisation
11:30-11:50
Interactive discussion to co-design an initial concept
11:50-12:00
Summary, next steps, Q&A
2. HORIZON-MISS-2024-CANCER-01-05: Improving the understanding and management of late-effects in adolescents and young adults (AYA) with cancer:
This topic will contribute to the achievement of the Mission’s objective to improve the quality of life of cancer patients, survivors and their families. The focus should be exclusively on adolescent and young adult (AYA, age range 15-39) cancer patients and survivors.
Each year, more than 150,000 AYA cancers are diagnosed in the EU, and over 1.2 million worldwide. About 300,000 AYA patients live with or beyond cancer in the EU; the majority experience late-effects due to their cancer treatment, including chronic pain, cardiovascular disease, organ and skin alterations, cosmetic sequelae, fertility problems, cognitive and functional impairment, and mental health issues such as depression and anxiety. Survivors may also be at increased risk of second cancers due to the long-term effects of radiation and chemotherapy. The negative impact on education and employment of AYA survivors and in general the financial burden borne by them is also commonly observed.
Late effects are particularly challenging for AYA cancer survivors, who often experience them during a critical phase of their lives. Late effects are also challenging for caregivers. The considerable progress made in treating AYA cancers has further exposed gaps in the understanding, prevention and management of late-effects, which warrant more targeted pan-European research on AYA cancer survivorship.
Read more about the call
Receive the EIT Hub Israel news and latest opportunities right to your inbox
Connect & Experience offers more than training. The C&E community network is an active EU online and offline community offering easy access to opportunities, curated content, matchmaking, soft landing services, and support. The community provides a space for community builders from Europe and Horizon Europe associated countries to interact, share best practices, and collaborate to enhance your startup community.
The Health not The Death is a fundamental human right. A healthy population is not to be seen as human and social capital, an input, or by-product, towards economic growth. Alongside a healthy and sustainable environment, a solidarity, a healthy population must be the ultimate goal especially nowadays in helping Ukrainian migrants with cancer and their families.
Solidarity in health is a cornerstone of EU health policy. There are wide disparities in many health outcomes across the region and those outcomes. The access rules dramatically affect healthcare systems which are at the forefront of the migrant way, the people who are searching for help and the way how we could enhance and support their healthier and wellbeing status.
In order to ensure their access to care and continued cure in need, the probability of receiving a timely diagnosis and of surviving differs greatly from country to country where they are now. There is lack of information, help and inequalities in access. People need help in navigating cancer knowledge, diagnostics, secondary monitoring and prevention, way of treatments, and care.
Shifting our mindset, supporting healthcare connectivity, removing inequalities overall across Europe is our mission and even more now in a time of crisis, helping the Ukrainian people dealing with cancer is a good place to begin this transformative revolution.
1) Whether we have a chance to foster more holistic and integrated approaches to receive information and care, by supporting coordination and maximising an enabling and health-enhancing effect of care across services from different countries?
2) Whether actions should address the social determinants of health, the countries where they are now, the health need which they have, the social and language barriers are the conditions which have to be taken into consideration in a coordinated manner?
How might we improve patients and /or people who seek healthcare support, access to healthcare services at an EU & the Member States Healthcare systems level? Especially in a time of crisis in Europe.
How might we support refugees fleeing from their countries by navigating them to medical centres to receive best available care?
Precision medicine aims to personalise care for every individual. Nongenomic and genomic determinants, combined with information from patient symptoms, clinical history, and lifestyle (nutrition, physical activity, stress etc.), can facilitate personalised diagnosis and prognostics. Yet this goal requires access to massive amounts of data which may come from different structured and unstructured sources; these can be our medical records, laboratory testing, a range of medical devices as well as from the patient himself. AI & ML can combine input from these multiple sources, analyse them and identify biomarkers that can support health professionals make more informed decisions. The convergence of precision medicine with the advanced AI capabilities will improve the ability to personalise care – improve diagnosis, risk prediction as well as therapy planning.
HCPs want to better predict treatment response, given uncertainty around which treatment to prescribe to which patient and when to prescribe. How do we risk assess the patients, match them with the right treatment (personalised). How can we transform the wealth of data and link it to the predictive nature of how the patient will respond?
Being diagnosed with cancer is overwhelming and comes as a blow. Patients may feel on a roller coaster of emotions—they are scared, lost & confused not knowing what to expect, who to refer to, what to do and how to tell their loved ones. They directly refer to “Dr. Google” to look for information about their disease, possible treatments, QoL strategies with the aim to have better understanding of their disease and learn how to better cope with their disease & treatment, yet information is not always valid, accessible, nor personalised or tailored to the patient’s status and needs therefore left with huge amounts of non-relevant information. Coming to the doctor, the physician’s time is limited and mostly focusing on the physical aspects of the disease & treatment, not leaving much time to ask questions nor discuss more holistic aspects of the disease such as emotional, psychological, social aspects. The patient (& caregiver in many cases) leaves the room with unanswered questions, doesn’t remember much of what has been said, and feels he is not heard, nor seen as a whole.
The need for navigating this journey along the emotional psychological stress is overwhelming & patients and their caregivers look for support (case manager/companion/partner) to help manage their disease holistically – starting from having clarity around their disease and treatment by having access to reliable and personalised information during their journey as well as having an integrated holistic care system , supporting them and their loved ones to navigate through the different aspects of their disease – medical, emotional, logistical, psychological, social, rights.
How can we support patients to navigate through the complexity of their disease and treatment ensuring they have validated holistic information about their disease journey & treatment and be empowered to effectively manage their care
As medical events pivoted from conference centres and meeting rooms to the virtual settings, learning opportunities continue. Lectures and presentations are translated to the new digital world, yet the ability to connect and network is relatively lost. Peer interaction is essential not only for information exchange but to share practical insights, allows consultation & in-person experience cross country and across borders leading to better disease management.
This peer-based learning/ consultation is highly valued amongst practising clinicians and was generally achieved when HCPs and KOLs met their peers in national & Intl conferences, group debates, advisory boards and even during quick corridor conversations. Attempting to replicate these in-person experiences into the digital space creates challenges and are not effective nor impactful as face-to-face engagements.
How might we improve HCP medical exchange enabling physicians to easily communicate, consult, exchange opinions leveraging individual experts & centres of excellence knowledge, experiences, and practices?
How can we leverage the technological expertise to allow HCPs to connect with leading experts across countries to get advice / counselling for their cases?
Application for 2022Calling2Scale is closed.
Interested in participating in the next cohort?
Email [email protected]
1. HORIZON-MISS-2024-CANCER-01-03: Accessible and affordable risk predictor tests to advance early detection of heritable cancers in European regions:
There is a need to validate, pilot, and upscale easy-to-use genetic, multi-omics or other biomarker-based tests for early detection of cancers with an underlying heritable genetic risk, for uptake in regional or national healthcare systems.
Read more about the call